Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Perioperative Toripalimab Plus Lenvatinib for Multi-stage ccRCC
NCT07571551Phase 2Recruiting
- Sponsor
- Jinling Hospital
- Start
- May 2026
- Primary completion
- Dec 2027
- Modality
- Immune Checkpoint Inhibitors, Recombinant Proteins and Enzymes, Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of toripalimab, lenvatinib in clear cell renal cell carcinoma (ccRCC), sponsored by Jinling Hospital. Started May 2026; status: recruiting.
02
Drugs
toripalimablenvatinib
03
Conditions
clear cell renal cell carcinoma (ccRCC)
Beyond the preview
Go deeper on NCT07571551.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07571551.